Spruce Biosciences to Present Findings on Retrospective Analysis of Completion Rates for CAH Studies at Pediatric Endocrine Society 2023 Annual Meeting
04 Mai 2023 - 10:05PM
Business Wire
Mitchell Geffner, M.D., to Present on May 7,
2023 from 12:30 pm – 2 pm PT
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage
biopharmaceutical company focused on developing and commercializing
novel therapies for rare endocrine disorders with significant unmet
medical need, today announced that a submitted abstract was
accepted for poster presentation at the Pediatric Endocrine Society
(PES) 2023 Annual Meeting taking place May 5-8, 2023, in San Diego,
Calif. Mitchell Geffner, M.D., will present findings on a
retrospective analysis of completion rates for adult and pediatric
congenital adrenal hyperplasia (CAH) studies.
Details are as follows:
Title: Clinical Trials in CAH: So Many Starting, but Not
So Many Finishing Abstract Number: 6407 Poster
Session: 3 Session Date & Time: Sunday, May 7, 2023
from 12:30 pm – 2 pm PT Presenter: Mitchell E. Geffner,
M.D., Co-Director of the Congenital Adrenal Hyperplasia
Comprehensive Care Clinic and Professor of Pediatrics, Keck School
of Medicine of University of Southern California Authors:
P.J. Ramtin, R. Will Charlton M.D., M.A.S., Mitchell E. Geffner
M.D.
Access more information about PES 2023 here.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company
focused on developing and commercializing novel therapies for rare
endocrine disorders with significant unmet medical need. Spruce is
initially developing its wholly-owned product candidate,
tildacerfont, as the potential first non-steroidal therapy for
patients suffering from classic congenital adrenal hyperplasia
(CAH). Spruce is also developing tildacerfont for women suffering
from polycystic ovary syndrome (PCOS) with primary adrenal androgen
excess. To learn more, visit www.sprucebiosciences.com and follow
us on Twitter @Spruce_Bio, LinkedIn, Facebook and YouTube.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230504005432/en/
Media Will Zasadny Evoke Canale (619) 961-8848
will.zasadny@evokecanale.com media@sprucebiosciences.com
Investors Xuan Yang Solebury Strategic Communications
(415) 971-9412 xyang@soleburystrat.com
investors@sprucebiosciences.com
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Spruce Biosciences (NASDAQ:SPRB)
Historical Stock Chart
Von Jan 2024 bis Jan 2025
